Article
CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
The Journal of pathology - 1 Jul 2018
Karkampouna Sofia, van der Helm Danny, Gray Peter C, Chen Lanpeng, Klima Irena, Grosjean Joël, Burgmans Mark C, Farina-Sarasqueta Arantza, Snaar-Jagalska Ewa B, Stroka Deborah M, Terracciano Luigi, van Hoek Bart, Schaapherder Alexander F, Osanto Susan, Thalmann George N, Verspaget Hein W, Coenraad Minneke J, Kruithof-de Julio Marianna
Abstract excerpt
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Despite increasing treatment options for this disease, prognosis remains poor. CRIPTO (TDGF1) protein is expressed at high levels in several human tumours and promotes oncogenic phenotype. Its expression has been correlated to poor prognosis in HCC. In this study, we aimed to elucidate the basis for the effects of CRIPTO...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.